Aqeel M Alenazi1,2, Sakher M Obaidat2,3, Mohammed M Alshehri2,4, Shaima Alothman2, Corey Gray2, Jason Rucker2, Lemuel R Waitman5, Patricia M Kluding2. 1. Department of Rehabilitation Sciences and Physical Therapy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia. 2. Department of Physical Therapy and Rehabilitation Science, University of Kansas, Medical Center, Kansas City, Kansas, USA. 3. Department of Rehabilitation Sciences, Hashemite University, Zarqa, Jordan. 4. Department of Rehabilitation Science, Jazan University, Jazan, Saudi Arabia. 5. Department of Internal Medicine, University of Kansas, Medical Center, Kansas City, Kansas, USA.
Abstract
OBJECTIVE: To examine the association between type 2 diabetes (T2D) and pain severity in people with localized osteoarthritis (OA) and to explore the association between glycemic control, measured by hemoglobin A1c (HbA1c) level, and pain severity in people with localized OA and T2D. DESIGN: Retrospective study. SETTING: A tertiary medical center. SUBJECTS: Data from 819 patients (mean age = 65.08±9.77 years, 54.3% women) were used. METHODS: Patients were grouped to localized OA only (N = 671) and localized OA+T2D (N = 148) based on diagnosis codes. An index date was set as the first diagnosis date of localized OA and linked to pain severity, measured by numeric rating scale from 0 to 10. HbA1c values were obtained for patients with T2D within six months of the index date. Multiple linear regression was used. RESULTS: After controlling for age, gender, body mass index (BMI); diagnoses of depression, hypertension, dyslipidemia; OA locations; and medication list (+/- 90 days of the index date), T2D was significantly associated with increased pain severity (B = 1.07, 95% confidence interval [CI] = 0.25 to 1.88, P = 0.014). For patients with T2D and localized OA with available data for HbA1c (N = 87), the results showed that an increased HbA1c value was significantly associated with higher pain severity (B = 0.36, 95% CI = 0.036 to 0.67, P = 0.029) after controlling for age, gender, BMI, medications, and OA locations. CONCLUSION: T2D was associated with higher pain severity in people with localized OA, and poor glycemic control was associated with higher pain severity in people with localized OA+T2D. Clinicians should emphasize that better HbA1c control might help with pain management in people with T2D and OA.
OBJECTIVE: To examine the association between type 2 diabetes (T2D) and pain severity in people with localized osteoarthritis (OA) and to explore the association between glycemic control, measured by hemoglobin A1c (HbA1c) level, and pain severity in people with localized OA and T2D. DESIGN: Retrospective study. SETTING: A tertiary medical center. SUBJECTS: Data from 819 patients (mean age = 65.08±9.77 years, 54.3% women) were used. METHODS:Patients were grouped to localized OA only (N = 671) and localized OA+T2D (N = 148) based on diagnosis codes. An index date was set as the first diagnosis date of localized OA and linked to pain severity, measured by numeric rating scale from 0 to 10. HbA1c values were obtained for patients with T2D within six months of the index date. Multiple linear regression was used. RESULTS: After controlling for age, gender, body mass index (BMI); diagnoses of depression, hypertension, dyslipidemia; OA locations; and medication list (+/- 90 days of the index date), T2D was significantly associated with increased pain severity (B = 1.07, 95% confidence interval [CI] = 0.25 to 1.88, P = 0.014). For patients with T2D and localized OA with available data for HbA1c (N = 87), the results showed that an increased HbA1c value was significantly associated with higher pain severity (B = 0.36, 95% CI = 0.036 to 0.67, P = 0.029) after controlling for age, gender, BMI, medications, and OA locations. CONCLUSION: T2D was associated with higher pain severity in people with localized OA, and poor glycemic control was associated with higher pain severity in people with localized OA+T2D. Clinicians should emphasize that better HbA1c control might help with pain management in people with T2D and OA.
Authors: Sandra A Atayde; Natalino H Yoshinari; Dafne P Nascimento; Sérgio Catanozi; Priscila C Andrade; Ana Paula P Velosa; Edwin R Parra; Marisa Passarelli; Edna R Nakandakare; Vera L Capelozzi; Walcy R Teodoro Journal: Histol Histopathol Date: 2012-11 Impact factor: 2.303
Authors: Jeffrey B Driban; Grace H Lo; Charles B Eaton; Kate L Lapane; Michael Nevitt; William F Harvey; Charles E McCulloch; Timothy E McAlindon Journal: Ther Adv Musculoskelet Dis Date: 2016-08-24 Impact factor: 5.346
Authors: Shawn N Murphy; Griffin Weber; Michael Mendis; Vivian Gainer; Henry C Chueh; Susanne Churchill; Isaac Kohane Journal: J Am Med Inform Assoc Date: 2010 Mar-Apr Impact factor: 4.497
Authors: Leah L Zullig; Hayden B Bosworth; Amy S Jeffreys; Leonor Corsino; Cynthia J Coffman; Eugene Z Oddone; William S Yancy; Kelli D Allen Journal: Clin Rheumatol Date: 2014-06-12 Impact factor: 2.980
Authors: Georg Schett; Arndt Kleyer; Carlo Perricone; Enijad Sahinbegovic; Annamaria Iagnocco; Jochen Zwerina; Rolando Lorenzini; Franz Aschenbrenner; Francis Berenbaum; Maria-Antonietta D'Agostino; Johann Willeit; Stefan Kiechl Journal: Diabetes Care Date: 2012-09-21 Impact factor: 19.112
Authors: Angela V Bedenbaugh; Machaon Bonafede; Elizabeth H Marchlewicz; Vinson Lee; Jeyanesh Tambiah Journal: Clinicoecon Outcomes Res Date: 2021-05-21
Authors: Aqeel M Alenazi; Mohammed M Alshehri; Shaima Alothman; Bader A Alqahtani; Jason Rucker; Neena K Sharma; Saad M Bindawas; Patricia M Kluding Journal: Phys Ther Date: 2020-10-30